16 September 2026 editorial review · Item
Oral insulin (antigen-specific immunotherapy): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: POInT primary endpoint neutral HR 1.12; genotype interactions hypothesis-generating. Corrected blanket zero-hypoglycemia claim: rare glucose <50 mg/dL measurements occurred in both arms. No general prevention indication.
- Registry NCT00419562: COMPLETED; updated 2020-05-07; enrollment 560 (ACTUAL); primary completion 2016-12 (ACTUAL); results posted.
- Registry NCT03364868: COMPLETED; updated 2024-10-08; enrollment 1050 (ACTUAL); primary completion 2024-06-28 (ACTUAL); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: dc15-1419; jama.2013.6285; bmjopen-2016-011144; S0140-6736%2825%2901726-X; jama.2015.2928; diacare.28.5.1068; jama.2017.17070.